HIGHLIGHTS
- who: Amer Raheemullah et al. from the Department of Psychiatry and Behavioral Sciences, School of Medicine, Stanford University, Stanford, CA, USA have published the research work: Buprenorphine Microdosing Cross Tapers: A Time for Change, in the Journal: (JOURNAL)
- what: The prescribing practices for buprenorphine in the US have been evolving as we learn more about the drug`s properties.
SUMMARY
Buprenorphine is a partial opioid agonist that is Food and Drug Administration (FDA) approved to treat chronic pain and opioid use disorder (OUD). The national prescribing guidelines in the United_States (US . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.